

IRB Approved at th Protocol Level Sep 28, 2022

About the Study

PURPOSE 2 is a clinical study to evaluate if Lenacapavir (LEN), an investigational medicine, given every 6 months can help to reduce the chance of getting HIV through sex (PrEP, or Pre-exposure Prophylaxis).



Please Contact

Meharry Clinical Research Team at 1005 Dr. DB Todd Jr. Blvd. or give us a call at 615-327-6353

Find out more about the PURPOSE studies here: www.purposestudies.com ClinicalTrials.gov ID: NCT04925752



Participants must:

- Be at least 18 years of age
- Not have had an HIV test in the past 3 months
- No oral PrEP in past 12 weeks or any prior use of long-acting systemic PrEP
- Be a cisgender man, transgender or gender nonbinary individual who has receptive anal sex
- Meet eligibility criteria during screening